• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于设计和发现治疗胃肠道疾病的嘌呤能药物的方法。

Approaches for designing and discovering purinergic drugs for gastrointestinal diseases.

机构信息

School of Pharmacy, Medicinal Chemistry Unit, University of Camerino , Camerino, Italy.

Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa , Pisa, Italy.

出版信息

Expert Opin Drug Discov. 2020 Jun;15(6):687-703. doi: 10.1080/17460441.2020.1743673. Epub 2020 Mar 31.

DOI:10.1080/17460441.2020.1743673
PMID:32228110
Abstract

INTRODUCTION

Purines finely modulate physiological motor, secretory, and sensory functions in the gastrointestinal tract. Their activity is mediated by the purinergic signaling machinery, including receptors and enzymes regulating their synthesis, release, and degradation. Several gastrointestinal dysfunctions are characterized by alterations affecting the purinergic system.

AREAS COVERED

The authors provide an overview on the purinergic receptor signaling machinery, the molecules and proteins involved, and a summary of medicinal chemistry efforts aimed at developing novel compounds able to modulate the activity of each player involved in this machinery. The involvement of purinergic signaling in gastrointestinal motor, secretory, and sensory functions and dysfunctions, and the potential therapeutic applications of purinergic signaling modulators, are then described.

EXPERT OPINION

A number of preclinical and clinical studies demonstrate that the pharmacological manipulation of purinergic signaling represents a viable way to counteract several gastrointestinal diseases. At present, the paucity of purinergic therapies is related to the lack of receptor-subtype-specific agonists and antagonists that are effective . In this regard, the development of novel therapeutic strategies should be focused to include tools able to control the P1 and P2 receptor expression as well as modulators of the breakdown or transport of purines.

摘要

简介

嘌呤类物质可精细调节胃肠道的生理运动、分泌和感觉功能。它们的活性由嘌呤能信号机制介导,包括调节其合成、释放和降解的受体和酶。几种胃肠道功能障碍的特征是影响嘌呤能系统的改变。

涵盖领域

作者概述了嘌呤能受体信号机制、涉及的分子和蛋白质,并总结了旨在开发能够调节该机制中每个参与者活性的新型化合物的药物化学努力。然后描述了嘌呤能信号在胃肠道运动、分泌和感觉功能及障碍中的作用,以及嘌呤能信号调节剂的潜在治疗应用。

专家意见

许多临床前和临床研究表明,嘌呤能信号的药理学调控是对抗多种胃肠道疾病的可行方法。目前,嘌呤能治疗方法的缺乏与缺乏有效的受体亚型特异性激动剂和拮抗剂有关。在这方面,新的治疗策略的发展应侧重于包括能够控制 P1 和 P2 受体表达以及嘌呤分解或转运调节剂的工具。

相似文献

1
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases.用于设计和发现治疗胃肠道疾病的嘌呤能药物的方法。
Expert Opin Drug Discov. 2020 Jun;15(6):687-703. doi: 10.1080/17460441.2020.1743673. Epub 2020 Mar 31.
2
The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.嘌呤能系统作为治疗免疫介导的炎症性疾病的药理学靶点。
Pharmacol Rev. 2019 Jul;71(3):345-382. doi: 10.1124/pr.117.014878.
3
The roles of purinergic signaling during gastrointestinal inflammation.嘌呤能信号在胃肠道炎症中的作用。
Curr Opin Pharmacol. 2012 Dec;12(6):659-66. doi: 10.1016/j.coph.2012.09.011. Epub 2012 Oct 11.
4
The Therapeutic Potential of Purinergic Receptors in Alzheimer's Disease and Promising Therapeutic Modulators.嘌呤能受体在阿尔茨海默病中的治疗潜力及有前景的治疗调节剂。
Mini Rev Med Chem. 2021;21(11):1288-1302. doi: 10.2174/1389557520999201209211610.
5
Therapeutic applications.治疗应用。
Subcell Biochem. 2011;55:235-76. doi: 10.1007/978-94-007-1217-1_9.
6
Tackling Chronic Pain and Inflammation through the Purinergic System.通过嘌呤能系统治疗慢性疼痛和炎症。
Curr Med Chem. 2018;25(32):3830-3865. doi: 10.2174/0929867324666170710110630.
7
Purinergic receptor-mediated morphological changes in microglia are transient and independent from inflammatory cytokine release.嘌呤能受体介导的小胶质细胞形态变化是短暂的,且与炎症细胞因子释放无关。
Eur J Pharmacol. 2010 Sep 25;643(2-3):202-10. doi: 10.1016/j.ejphar.2010.06.046. Epub 2010 Jul 13.
8
The role of purinergic pathways in the pathophysiology of gut diseases: pharmacological modulation and potential therapeutic applications.嘌呤能途径在肠道疾病病理生理学中的作用:药理学调节及其潜在的治疗应用。
Pharmacol Ther. 2013 Aug;139(2):157-88. doi: 10.1016/j.pharmthera.2013.04.002. Epub 2013 Apr 13.
9
Involvement of purinergic signaling in cardiovascular diseases.嘌呤能信号传导在心血管疾病中的作用。
Drug News Perspect. 2003 Apr;16(3):133-40. doi: 10.1358/dnp.2003.16.3.876886.
10
Purinergic Mechanisms and Pain.嘌呤能机制与疼痛
Adv Pharmacol. 2016;75:91-137. doi: 10.1016/bs.apha.2015.09.001. Epub 2015 Nov 4.

引用本文的文献

1
Topical ATP Application in the Peripheral Swallowing-Related Regions Facilitates Triggering of the Swallowing Reflex Involving P2X3 Receptors.在外周吞咽相关区域局部应用三磷酸腺苷(ATP)可促进涉及P2X3受体的吞咽反射触发。
Function (Oxf). 2025 Mar 24;6(2). doi: 10.1093/function/zqaf010.
2
Tartary Buckwheat Bran and Fructus Aurantii Combination (TBB-FA): A Promising Therapeutic Approach for Functional Dyspepsia via Modulation of Gut Microbiota, Short-Chain Fatty Acids and Purine Signaling Pathway.苦荞麸皮与枳壳组合(TBB-FA):通过调节肠道微生物群、短链脂肪酸和嘌呤信号通路治疗功能性消化不良的一种有前景的方法。
Food Sci Nutr. 2025 Jan 12;13(1):e4695. doi: 10.1002/fsn3.4695. eCollection 2025 Jan.
3
Dynamic recycling of extracellular ATP in human epithelial intestinal cells.
人类肠道上皮细胞细胞外 ATP 的动态再循环。
PLoS Comput Biol. 2023 Jun 29;19(6):e1011196. doi: 10.1371/journal.pcbi.1011196. eCollection 2023 Jun.
4
Purinergic Signaling in Oral Tissues.嘌呤能信号在口腔组织中的作用。
Int J Mol Sci. 2022 Jul 14;23(14):7790. doi: 10.3390/ijms23147790.
5
Anti-inflammatory Effects of Novel P2X4 Receptor Antagonists, NC-2600 and NP-1815-PX, in a Murine Model of Colitis.新型 P2X4 受体拮抗剂 NC-2600 和 NP-1815-PX 在结肠炎小鼠模型中的抗炎作用。
Inflammation. 2022 Aug;45(4):1829-1847. doi: 10.1007/s10753-022-01663-8. Epub 2022 Mar 26.
6
Targeting GATA1 and p2x7r Locus Binding in Spinal Astrocytes Suppresses Chronic Visceral Pain by Promoting DNA Demethylation.靶向脊髓星形胶质细胞中的 GATA1 和 p2x7r 基因座结合可通过促进 DNA 去甲基化来抑制慢性内脏痛。
Neurosci Bull. 2022 Apr;38(4):359-372. doi: 10.1007/s12264-021-00799-1. Epub 2021 Dec 10.
7
Purinergic Signaling: Impact of GPCR Structures on Rational Drug Design.嘌呤能信号转导:G 蛋白偶联受体结构对合理药物设计的影响。
ChemMedChem. 2020 Nov 4;15(21):1958-1973. doi: 10.1002/cmdc.202000465. Epub 2020 Sep 18.
8
The Adenosine System at the Crossroads of Intestinal Inflammation and Neoplasia.肠炎症与肿瘤的十字路口处的腺苷系统。
Int J Mol Sci. 2020 Jul 18;21(14):5089. doi: 10.3390/ijms21145089.
9
The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A Receptor Agonist, in a Rat Model of Colitis.腺苷 A 受体激动剂 AR170 在结肠炎大鼠模型中的抗炎和止痛作用。
Cells. 2020 Jun 21;9(6):1509. doi: 10.3390/cells9061509.
10
Glial A Adenosine Receptors Modulate Abnormal Tachykininergic Responses and Prevent Enteric Inflammation Associated with High Fat Diet-Induced Obesity.神经胶质细胞 A 型腺苷受体调节异常速激肽反应,预防高脂肪饮食诱导肥胖相关的肠道炎症。
Cells. 2020 May 18;9(5):1245. doi: 10.3390/cells9051245.